2-Chloro-3-methylbenzenethiol | 90825-53-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯硫酚类
• 英文名称: 2-Chloro-3-methylbenzenethiol
• CAS: 90825-53-9
• 化学式: C₇H₇ClS
• 分子量: 158.65
• InChiKey: STTATAFZCQSICP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  1
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• [EN] BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS<br/>[FR] BENZOIMIDAZOLES COMME INHIBITEURS DE LA PROLYL HYDROXYLASE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2009134750A1

  公开（公告）日：2009-11-05

  The present invention is directed to benzoimidazole compounds of the formula (1) and enantiomers, diastereomers, racemates, and pharmaceutically acceptable salts thereof. Compounds of the present invention are useful in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions modulated by prolyl hydroxylase activity.

  本发明涉及公式（1）的苯并咪唑化合物及其对映体、二对映体、消旋体和药学上可接受的盐。本发明的化合物在制药组合物和治疗由脯氨酸羟化酶活性调节的疾病状态、紊乱和条件的方法中是有用的。
• BENZOIMIDAZOLES AS PROLYL HYDROXYLASE INHIBITORS
  申请人：Hocutt Frances Meredith

  公开号：US20110046132A1

  公开（公告）日：2011-02-24

  The present invention is directed to benzoimidazole compounds of the formula (1) and enantiomers, diastereomers, racemates, and pharmaceutically acceptable salts thereof. Compounds of the present invention are useful in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions modulated by prolyl hydroxylase activity.

  本发明涉及公式（1）的苯并咪唑化合物及其对映体、二对映异构体、外消旋体和药学上可接受的盐。本发明化合物在制药组合物和治疗疾病状态、紊乱和通过脯氨酸羟化酶活性调节的疾病条件的方法中是有用的。
• PHTHALOCYANINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND OPTICAL RECORDING MEDIUM CONTAINING THE SAME
  申请人：MITSUI CHEMICALS, INC.

  公开号：EP1482013A1

  公开（公告）日：2004-12-01

  A phthalocyanine compound represented by the following general formula (I) and the mixture thereof, and an optical recording medium containing the compound/mixture in its recording layer. wherein in formula (I), M is two hydrogen atoms, a divalent metal atom, a mono-substituted trivalent metal atom, a di-substituted tetravalent metal atom, or an oxymetal, and L1, L2, L3 and L4 are each independently formula (a), formula (b), or formula (c) : in formula (a), formula (b), and formula (c), X represents a substituted or unsubstituted alkyl group, alkoxy group, alkylthio group, aryloxy group, and arylthio group, Rs are each independently a hydrogen atom, a substituted or unsubstituted alkyl group with 1-6 of total carbon numbers, a substituted or unsubstituted aryl group with 6-10 of total carbon numbers, A represents a carbonyl group, a thiocarbonyl group, a sulfone group, a sulfine group, or a carboimidoyl group, Y represents a metal compound residue, and Z represents independently a hydrogen atom, a nitro group, or a halogen atom, and at least one of L1-L4 is formula (a) or (b).

  由以下通式(I)表示的酞菁化合物及其混合物，以及在其记录层中含有该化合物/混合物的光学记录介质。 其中，在式 (I) 中，M 是两个氢原子、二价金属原子、一取代三价金属原子、二取代四价金属原子或氧金属；L1、L2、L3 和 L4 各自独立地为式 (a)、式 (b) 或式 (c) ： 在式(a)、式(b)和式(c)中，X 代表取代或未取代的烷基、烷氧基、烷硫基、芳氧基和芳硫基，Rs 各自独立地为氢原子、总碳数为 1-6 的取代或未取代的烷基、A 代表羰基、硫代羰基、砜基、硫基或羧酰亚胺基，Y 代表金属化合物残基，Z 独立地代表氢原子、硝基或卤素原子，L1-L4 中至少有一个是式 (a) 或 (b)。
• Benzoimidazoles as prolyl hydroxylase inhibitors
  申请人：Janssen Pharmaceutica NV

  公开号：US10851083B2

  公开（公告）日：2020-12-01

  The present invention is directed to benzoimidazole compounds of the formula: and enantiomers, diastereomers, racemates, and pharmaceutically acceptable salts thereof. Compounds of the present invention are useful in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions modulated by prolyl hydroxylase activity.

  本发明涉及式中的苯并咪唑化合物： 及其对映体、非对映体、外消旋体和药学上可接受的盐。本发明化合物可用于治疗受脯氨酰羟化酶活性调节的疾病状态、失调和病症的药物组合物和方法中。
• Aza-pyridone compounds and uses thereof
  申请人：Janssen BioPharma, Inc.

  公开号：US10980805B2

  公开（公告）日：2021-04-20

  Disclosed herein are aza-pyridone compounds, pharmaceutical compositions that include one or more aza-pyridone compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an orthomyxovirus infection, with an aza-pyridone compounds. Examples of an orthomyxovirus viral infection include an influenza infection.

  本文公开了偶氮吡啶酮化合物、包括一种或多种偶氮吡啶酮化合物的药物组合物，以及合成这些化合物的方法。本文还公开了使用氮杂吡啶酮化合物改善和/或治疗疾病和/或病症（包括正粘病毒感染）的方法。正粘病毒感染的例子包括流感病毒感染。